[go: up one dir, main page]

CU23576A1 - Antígenos vacunales quiméricos contra el virus de la influenza aviar - Google Patents

Antígenos vacunales quiméricos contra el virus de la influenza aviar

Info

Publication number
CU23576A1
CU23576A1 CU20060051A CU20060051A CU23576A1 CU 23576 A1 CU23576 A1 CU 23576A1 CU 20060051 A CU20060051 A CU 20060051A CU 20060051 A CU20060051 A CU 20060051A CU 23576 A1 CU23576 A1 CU 23576A1
Authority
CU
Cuba
Prior art keywords
chimeric
antigens
influenza virus
avian influenza
vaccine
Prior art date
Application number
CU20060051A
Other languages
English (en)
Inventor
Nordelo Carlos Guillermo Borroto
Baile Nancy Elena Figueroa
Archer Damarys Diaz
Ramos Oliberto Sanchez
Alonso Jorge Roberto Toledo
Molto Maria Pilar Rodriguez
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20060051A priority Critical patent/CU23576A1/es
Priority to CL2007000526A priority patent/CL2007000526A1/es
Priority to ARP070100807A priority patent/AR059647A1/es
Priority to MX2008011143A priority patent/MX2008011143A/es
Priority to RU2008138535/13A priority patent/RU2008138535A/ru
Priority to EP07711103A priority patent/EP1997831A1/en
Priority to BRPI0708383-1A priority patent/BRPI0708383A2/pt
Priority to PCT/CU2007/000009 priority patent/WO2007098718A1/es
Priority to CNA200780013590XA priority patent/CN101421302A/zh
Priority to KR1020087023743A priority patent/KR20080113217A/ko
Priority to US12/280,568 priority patent/US20090324644A1/en
Priority to AU2007219571A priority patent/AU2007219571A1/en
Priority to JP2008556645A priority patent/JP2009528305A/ja
Priority to CA002638832A priority patent/CA2638832A1/en
Publication of CU23576A1 publication Critical patent/CU23576A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención describe antígenos vacunales quiméricos contra el virus de la influenza Aviar (IA).Dichos antígenos vacunales están basados en subunidades virales que están acopladas a moléculas proteicas estimuladoras del sistema inmune, tanto celular como humoral. Los antígenos quiméricos pueden ser producidos en sistemas de expresión que garantizan un correcto plegamiento tridimensional de las moléculas quiméricas que constituyen la base de la presente invención. Las composiciones vacunales que contienen dichos antígenos quiméricos inducen a una respuesta inmune potente y temprana tanto en las aves como en los mamíferos vacunados, estimulando altos títulos de anticuerpos inhibidores de la hematoglutación y una potente respuesta celular específica contra el antígeno viral. Los antígenos quiméricos, así como las composiciones vacunales resultantes son aplicables a la esfera de la salud humana y animal, como vacunas para uso preventivo.
CU20060051A 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la influenza aviar CU23576A1 (es)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CU20060051A CU23576A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la influenza aviar
CL2007000526A CL2007000526A1 (es) 2006-02-28 2007-02-27 Antigeno vacunal quimerico contra el virus de la influenza aviar, ia, que contiene el segmento extracelular de la hemaglutinina de la envoltura del virus de ia y el segmento extracelular de la proteina cd154; y composicion que lo comprende.
ARP070100807A AR059647A1 (es) 2006-02-28 2007-02-27 Antigenos vacunales quimericos contra el virus de la influenza aviar
MX2008011143A MX2008011143A (es) 2006-02-28 2007-02-28 Antigenos vacunales quimericos contra el virus de la influenza aviar.
RU2008138535/13A RU2008138535A (ru) 2006-02-28 2007-02-28 Химерные антигены вакцин против вируса птичьего гриппа
EP07711103A EP1997831A1 (en) 2006-02-28 2007-02-28 Chimeric vaccine antigens against the avian influenza virus
BRPI0708383-1A BRPI0708383A2 (pt) 2006-02-28 2007-02-28 antìgeno vacinal quimérico contra o vìrus da influenza aviário e composição de vacina capaz de produzir uma resposta imune protetora contra vìrus da influenza aviária em aves e em mamìferos
PCT/CU2007/000009 WO2007098718A1 (es) 2006-02-28 2007-02-28 Antígenos vacunales quiméricos contra el virus de la influenza aviar
CNA200780013590XA CN101421302A (zh) 2006-02-28 2007-02-28 针对禽流感病毒的嵌合疫苗抗原
KR1020087023743A KR20080113217A (ko) 2006-02-28 2007-02-28 조류 인플루엔자 바이러스에 대한 키메릭 백신 항원
US12/280,568 US20090324644A1 (en) 2006-02-28 2007-02-28 Chimeric vaccine antigens against the avian influenza virus
AU2007219571A AU2007219571A1 (en) 2006-02-28 2007-02-28 Chimeric vaccine antigens against the avian influenza virus
JP2008556645A JP2009528305A (ja) 2006-02-28 2007-02-28 鳥インフルエンザウイルスに対するキメラワクチン抗原
CA002638832A CA2638832A1 (en) 2006-02-28 2007-02-28 Chimeric vaccine antigens against the avian influenza virus

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060051A CU23576A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la influenza aviar

Publications (1)

Publication Number Publication Date
CU23576A1 true CU23576A1 (es) 2010-09-30

Family

ID=40130782

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20060051A CU23576A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la influenza aviar

Country Status (14)

Country Link
US (1) US20090324644A1 (es)
EP (1) EP1997831A1 (es)
JP (1) JP2009528305A (es)
KR (1) KR20080113217A (es)
CN (1) CN101421302A (es)
AR (1) AR059647A1 (es)
AU (1) AU2007219571A1 (es)
BR (1) BRPI0708383A2 (es)
CA (1) CA2638832A1 (es)
CL (1) CL2007000526A1 (es)
CU (1) CU23576A1 (es)
MX (1) MX2008011143A (es)
RU (1) RU2008138535A (es)
WO (1) WO2007098718A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ601880A (en) 2007-11-01 2013-12-20 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria
SG175382A1 (en) * 2009-04-30 2011-12-29 Cytos Biotechnology Ag Influenza hemagglutinin compositions and uses thereof
TW201738562A (zh) * 2009-05-28 2017-11-01 亞培生物股份有限公司 體外病原體檢驗技術
KR101262300B1 (ko) * 2009-10-06 2013-05-20 헬릭스 주식회사 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법
US9795661B2 (en) 2009-11-16 2017-10-24 The United States Of America As Represented By The Secretary Of The Navy TH1/TH2 polarizing vaccines
AR095313A1 (es) 2013-03-15 2015-10-07 Univ Arkansas Composiciones y métodos para aumentar la respuesta inmune contra patógenos entéricos
KR101582490B1 (ko) 2014-04-14 2016-01-19 아이디바이오 주식회사 인플루엔자 바이러스의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 바이러스 백신
MX2018013331A (es) 2016-05-03 2019-06-10 Univ Arkansas Vector de vacuna de levadura que incluye polipeptidos inmunoestimuladores y antigenicos y metodos para su uso.
KR101964044B1 (ko) * 2018-03-14 2019-04-02 인제대학교 산학협력단 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼
CN112679586A (zh) * 2020-12-28 2021-04-20 乾元浩生物股份有限公司 H5、h7亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN114106113B (zh) * 2021-11-13 2024-04-19 江苏南农高科技股份有限公司 一种表达猪细小病毒vp2蛋白的重组杆状病毒、制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US20020136722A1 (en) * 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
CU23102A1 (es) * 2002-10-21 2005-12-20 Ct Ingenieria Genetica Biotech Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein

Also Published As

Publication number Publication date
US20090324644A1 (en) 2009-12-31
AU2007219571A1 (en) 2007-09-07
JP2009528305A (ja) 2009-08-06
RU2008138535A (ru) 2010-04-10
MX2008011143A (es) 2008-09-08
KR20080113217A (ko) 2008-12-29
CN101421302A (zh) 2009-04-29
WO2007098718A8 (es) 2008-12-18
EP1997831A1 (en) 2008-12-03
CL2007000526A1 (es) 2009-03-27
AR059647A1 (es) 2008-04-16
BRPI0708383A2 (pt) 2011-05-24
CA2638832A1 (en) 2007-09-07
WO2007098718A1 (es) 2007-09-07

Similar Documents

Publication Publication Date Title
CU23576A1 (es) Antígenos vacunales quiméricos contra el virus de la influenza aviar
CY1121789T1 (el) Νεες ανοσοενισχυτικες συνθεσεις
MX2018007860A (es) Vacunas recombinantes contra el zika.
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
CR10559A (es) Vacuna de influenza
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
RU2010116187A (ru) Способ получения вируса гриппа
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
EA200701786A1 (ru) Поливалентная противогриппозная иммуногенная композиция
Dabaghian et al. Vaccination with recombinant 4× M2e. HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens
CU23544A1 (es) Antígenos vacunales quiméricos contra el virus de la peste porcina clásica
BR112014026744A8 (pt) anticorpo isolado ou fragmento de anticorpo, composição de anticorpo ou composição de fragmento de anticorpo, uso de modulação imune, uso de pelo menos uma composição de anticorpo ou fragmento de anticorpo, dispositivo médico, formulação, kit, artigo de fabricação para uso farmacêutico humano, método para produzir um anticorpo ou fragmento, animal ou planta transgênica, e, anticorpo ou porção ou variante especificada.
PE20151588A1 (es) Vacuna contra el virus del dengue
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
BR112016002354A2 (pt) composição imunogênica, métodos para proteger um bebê contra infecção ou doença e para evocar uma resposta imune, regime de vacinação, e, kit
Morçӧl et al. Calcium phosphate nanoparticle (CaPNP) for dose-sparing of inactivated whole virus pandemic influenza A (H1N1) 2009 vaccine in mice
Shrestha et al. Canine zona pellucida glycoprotein-3: up-scaled production, immunization strategy and its outcome on fertility
CO2017002614A2 (es) Vacuna emulsionada para obtener formulaciones de inmunoglobulinas igy concentradas; procesos y usos de las mismas.
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
EA201692375A1 (ru) Антитело-опосредованные вакцины и способы их применения для получения быстрых зрелых иммунных ответов
AR082577A1 (es) Vacunas de virus varicela zoster inactivado, metodos de produccion y uso de las mismas
BR112012022059A8 (pt) Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
MX2016000107A (es) Osteopontina lactea de mamifero para mejorar la capacidad de respuesta inmunitaria.